Find out how you can get the best content on Seeking Alpha here. We are short shares of Principia Biopharma (NASDAQ: PRNB), a company whose $2 billion valuation rests on a single obscure molecule ...

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to ...

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies ...

Principia’s Bruton tyrosine kinase (BTK) inhibitors add to Sanofi’s efforts to accelerate and build a portfolio of the next generation of transformative treatments for autoimmune diseases.

Patient improvement during Phase 2 trial of Principia's drug likely caused not by the drug but by regression to the mean. We believe secondary-endpoint results were likely not statistically ...

SAN FRANCISCO, Oct. 29, 2012 -- SAN FRANCISCO, Oct. 29, 2012 /PRNewswire/ -- Principia Biopharma, Inc., a privately-held biopharmaceutical company focused on advancing best-in-class medicines in ...

Sanofi’s Principia Biopharma is taking a one-two punch. Just days after one of the subsidiary's key BTK inhibitors crashed out of clinical testing, Sanofi has now disclosed it will wind down ...

March 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sanofi will develop Principia Biopharma’s Phase I central nervous system (CNS) candidate PRN2246 as a treatment for multiple sclerosis (MS), through a collaboration that could generate up to $ ...

Principia Biopharma Inc. said its initial public offering raised about $106 million to fund development of oral therapeutics focused on immunology and oncology. The South San Francisco ...

PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 /PRNewswire/ -- Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for ...